{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:43:31Z","timestamp":1793310211485,"version":"4.5.0"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100005052","name":"DST-Nanomission, India","doi-asserted-by":"publisher","award":["SR\/NM\/ NS\u201320\/2014"],"award-info":[{"award-number":["SR\/NM\/ NS\u201320\/2014"]}],"id":[{"id":"10.13039\/501100005052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board (SERB) India","doi-asserted-by":"publisher","award":["YSS\/2015\/ 000010"],"award-info":[{"award-number":["YSS\/2015\/ 000010"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2019,2,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Search for new antiviral and anticancer agents are essential because of the emergence of drug resistance in recent years. In continuation of our efforts in identifying the new small molecule antiviral and anticancer agents, we identified chalcones as potent antiviral and anticancer agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>With the aim of identifying the broad acting antiviral and anticancer agents, we discovered substituted aryl\/heteroaryl derived thienyl chalcones as antiviral and anticancer agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A focused set of thienyl chalcone derivaties II-VI was screened for selected viruses Hepatitis B virus (HBV), Herpes simplex virus 1 (HSV-1), Human cytomegalovirus (HCMV), Dengue virus 2 (DENV2), Influenza A (H1N1) virus, MERS coronavirus, Poliovirus 1 (PV 1), Rift Valley fever (RVF), Tacaribe virus (TCRV), Venezuelan equine encephalitis virus (VEE) and Zika virus (ZIKV) using the National Institute of Allergy and Infectious Diseases (NIAID)\u2019s Division of Microbiology and Infectious Diseases (DMID) antiviral screening program. Additionally, a cyclopropylquinoline derivative IV has been screened for 60 human cancer cell lines using the Development Therapeutics Program (DTP) of NCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All thienyl chalcone derivatives II-VI displayed moderate to excellent antiviral activity towards several viruses tested. Compounds V and VI were turned out be active compounds towards human cytomegalovirus for both normal strain (AD169) as well as resistant isolate (GDGr K17). Particularly, cyano derivative V showed very high potency (EC50: &lt;0.05 \u00b5M) towards AD169 strain of HCMV compared to standard drug Ganciclovir (EC50: 0.12 \u00b5M). Additionally, it showed moderate activity in the secondary assay (AD169; EC50: 2.30 \u00b5M). The cyclopropylquinoline derivative IV displayed high potency towards Rift Valley fever virus (RVFV) and Tacaribe virus (TCRV) towards Rift Valley fever virus (RVFV). The cyclopropylquinoline derivative IV is nearly 28 times more potent in our initial in vitro visual assay (EC50: 0.39 \u00b5g\/ml) and nearly 17 times more potent in neutral red assay (EC50: 0.71 \u03bcg\/ml) compared to the standard drug Ribavirin (EC50: 11 \u00b5g\/ml; visual assay and EC50: 12 \u00b5g\/ml; neutral red assay). It is nearly 12 times more potent in our initial in vitro visual assay (EC50: &gt;1 \u00b5g\/ml) and nearly 8 times more potent in neutral red assay (EC50: &gt;1.3 \u00b5g\/ml) compared to the standard drug Ribavirin (EC50: 12 \u00b5g\/ml; visual assay and EC50: 9.9 \u00b5g\/ml; neutral red assay) towards Tacaribe virus (TCRV). Additionally, cyclopropylquinoline derivative IV has shown strong growth inhibitory activity towards three major cancers (colon, breast, and leukemia) cell lines and moderate growth inhibition shown towards other cancer cell lines screened.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compounds V and VI were demonstrated viral inhibition towards Human cytomegalovirus, whereas cyclopropylquinoline derivative IV towards Rift Valley fever virus and Tacaribe virus. Additionally, cyclopropylquinoline derivative IV has displayed very good cytotoxicity against colon, breast and leukemia cell lines in vitro.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573406414666180524074648","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T03:58:22Z","timestamp":1527134302000},"page":"150-161","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities"],"prefix":"10.2174","volume":"15","author":[{"given":"Vikrant","family":"Patil","sequence":"first","affiliation":[{"name":"Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagaram, Bangalore 562112, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddappa A.","family":"Patil","sequence":"additional","affiliation":[{"name":"Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagaram, Bangalore 562112, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renukadevi","family":"Patil","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Bugarin","sequence":"additional","affiliation":[{"name":"Department of Chemistry & Biochemistry, University of Texas at Arlington, Arlington, TX 76019, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Beaman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaputra A.","family":"Patil","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"vew014","DOI":"10.1093\/ve\/vew014","volume":"2","author":"Irwin K.K.","year":"2016","unstructured":"Irwin KK, Renzette N, Kowalik TF, Jensen JD. Virus Evol, Antiviral drug resistance as an adaptive process.,, 2016, 2,, vew014-,","journal-title":"Virus Evol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/1573406413666170330094822","volume":"13","author":"Patil S.A.","year":"2017","unstructured":"Patil SA, Patil V, Patil R, Beaman K, Patil SA. Med Chem, Identification of novel 5,6-dimethoxyindan-1-one derivatives as antiviral agents.,, 2017, 13,, 787-795,","journal-title":"Med Chem"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bmcl.2017.01.089","volume":"27","author":"Patil R.","year":"2017","unstructured":"Patil R, Ghosh ASun, Cao . Bioorg Med Chem Lett, P.; Sommer, R.D.; Grice, K.A.; Waris, G.; Patil, S. Novel 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents.,, 2017, 27,, 1129-1135,","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"Siegel R.L.","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. CA Cancer J Clin, Cancer statistics, 2016.,, 2016, 66,, 7-30,","journal-title":"CA Cancer J Clin"},{"key":"ref=5","author":"","unstructured":"Available at, . www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2016, , ,"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1125951","volume":"312","author":"Baselga J.","year":"2006","unstructured":"Baselga J. Science, Targeting tyrosine kinases in cancer: The second wave.,, 2006, 312,, 1175-1178,","journal-title":"Science"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00003495-200363050-00005","volume":"63","author":"Croom K.F.","year":"2003","unstructured":"Croom KF, Perry CM. Drugs, Imatinibmesylate: in the treatment of gastrointestinal stromal tumors.,, 2003, 63,, 513-522,","journal-title":"Drugs"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"Druker B.J.","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. N Engl J Med, Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia.,, 2001, 344,, 1031-1037,","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1016\/j.bmcl.2012.04.074","volume":"22","author":"Patil S.A.","year":"2012","unstructured":"Patil SA, Wang J, Li XS, Chen J, Jones TS, Hosni-Ahmed A, Patil R, Seibel WL, Li W, Miller DD. Bioorg Med Chem Lett, New substituted 4H-chromenes as anticancer agents.,, 2012, 22,, 4458-4461,","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1573406410666140914162701","volume":"11","author":"Patil S.A.","year":"2015","unstructured":"Patil SA, Pfeffer SR, Seibel WL, Pfeffer LM, Miller DD. Med Chem, Identification of imidazoquinoline derivatives as potent antiglioma agents.,, 2015, 11,, 400-406,","journal-title":"Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/157340608786242070","volume":"4","author":"Maria K.","year":"2008","unstructured":"Maria K, Dimitra HL, Maria G. Med Chem, Synthesis and anti-inflammatory activity of chalcones and related Mannich bases.,, 2008, 4,, 586-596,","journal-title":"Med Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm200946h","volume":"54","author":"Wu J.","year":"2011","unstructured":"Wu J, Li J, Cai Y, Pan Y, Ye F, Zhang Y, Zhao Y, Yang S, Li X, Liang G. J Med Chem, Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents.,, 2011, 54,, 8110-8123,","journal-title":"J Med Chem"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2006.09.019","volume":"42","author":"Nowakowska Z.","year":"2007","unstructured":"Nowakowska Z. Eur J Med Chem, A review of anti-infective and anti-inflammator chalcones.,, 2007, 42,, 125-137,","journal-title":"Eur J Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/jf0002995","volume":"48","author":"Miranda C.L.","year":"2000","unstructured":"Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, Buhler DR. J Agric Food Chem, Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones .,, 2000, 48,, 3876-3884,","journal-title":"J Agric Food Chem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.bmcl.2008.09.105","volume":"18","author":"Chiaradia L.D.","year":"2008","unstructured":"Chiaradia LD, Mascarello A, Purifica\u00e7\u00e3o M, Vernal J, Cordeiro MNS, Zenteno ME, Villarino A, Nunes RJ, Yunes RA, Terenzi H. Bioorg Med Chem Lett, Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.,, 2008, 18,, 6227-6230,","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0960-894X(03)00197-5","volume":"13","author":"Wu J.H.","year":"2003","unstructured":"Wu JH, Wang XH, Yi YH, Lee KH. Bioorg Med Chem Lett, Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos.,, 2003, 13,, 1813-1815,","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0223-5234(01)01245-4","volume":"36","author":"Dom\u00ednguez J.N.","year":"2001","unstructured":"Dom\u00ednguez JN, Charris JE, Lobo G, Gamboa de Dom\u00ednguez N, Moreno MM, Riggione F, Sanchez E, Olson J, Rosenthal PJ. Eur J Med Chem, Synthesis of quinolinylchalcones and evaluation of their antimalarial activity.,, 2001, 36,, 555-560,","journal-title":"Eur J Med Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/0929867306666220401182509","volume":"6","author":"Dimmock J.R.","year":"1999","unstructured":"Dimmock JR, Elias DW, Beazely MA, Kandepu NM. Curr Med Chem, Bioactivities of chalcones.,, 1999, 6,, 1125-1149,","journal-title":"Curr Med Chem"},{"key":"ref=19","first-page":"3647","volume":"1","author":"Patil V.","year":"2016","unstructured":"Patil V, Barragan E, Patil SA, Patil SA, Bugarin A. Chem Select, Direct synthesis and antimicrobial evaluation of structurally complex chalcones.,, 2016, 1,, 3647-,","journal-title":"Chem Select"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","volume":"57","author":"Prichard M.N.","year":"2013","unstructured":"Prichard MN, Williams JD, Komazin-Meredith G, Khan AR, Price NB, Jefferson GM, Harden EA, Hartline CB, Peet NP, Bowlin TL. Antimicrob Agents Chemother, Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.,, 2013, 57,, 3518-3527,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.45.3.743-748.2001","volume":"45","author":"Smee D.F.","year":"2001","unstructured":"Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. Antimicrob Agents Chemother, Cyclopentane neuraminidase inhibitors with potent anti-influenza virus activities.,, 2001, 45,, 743-748,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2016.04.003","volume":"131","author":"Smee D.F.","year":"2016","unstructured":"Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Antiviral Res, Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.,, 2016, 131,, 61-65,","journal-title":"Antiviral Res"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0166-3542(92)90056-B","volume":"19","author":"Korba B.E.","year":"1992","unstructured":"Korba BE, Gerin JL. Antiviral Res, Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication.,, 1992, 19,, 55-70,","journal-title":"Antiviral Res"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0166-3542(91)90068-3","volume":"15","author":"Korba B.E.","year":"1991","unstructured":"Korba BE, Milman G. Antiviral Res, A cell culture assay for compounds which inhibit hepatitis B virus replication.,, 1991, 15,, 217-228,","journal-title":"Antiviral Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","volume":"34","author":"Boyd M.R.","year":"1995","unstructured":"Boyd MR, Paull KD. Drug Dev Res, Some practical considerations and applications of the National Cancer Institute anticancer drug discovery screen.,, 1995, 34,, 91-109,","journal-title":"Drug Dev Res"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","volume":"9","author":"Holbeck S.L.","year":"2010","unstructured":"Holbeck SL, Collins JM, Doroshow JH. Mol Cancer Ther, Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.,, 2010, 9,, 1451-1460,","journal-title":"Mol Cancer Ther"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1535-7163.MCT-06-0787","volume":"6","author":"Covell D.G.","year":"2007","unstructured":"Covell DG, Huang R, Wallqvist A. Mol Cancer Ther, Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data.,, 2007, 6,, 2261-2270,","journal-title":"Mol Cancer Ther"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"Skehan P.","year":"1990","unstructured":"Skehan P, Streng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd M. J Natl Cancer Inst, New colorimetric cytotoxicity assay for anticancer-drug screening.,, 1990, 82,, 1107-1112,","journal-title":"J Natl Cancer Inst"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"11","author":"Monks A.","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M. J Natl Cancer Inst, Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell Lines.,, 1991, 11,, 757-766,","journal-title":"J Natl Cancer Inst"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-8278(00)80418-3","volume":"32","author":"Lok A.S.","year":"2000","unstructured":"Lok AS. J Hepatol, Hepatitis B infection: pathogenesis and management.,, 2000, 32,, 89-97,","journal-title":"J Hepatol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","volume":"28","author":"Shepard C.W.","year":"2006","unstructured":"Shepard CW, Simard EP, Finelli L, Fiore E, Bell BP. Epidemiol Rev, Hepatitis B virus infection: epidemiology and vaccination.,, 2006, 28,, 112-125,","journal-title":"Epidemiol Rev"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1016\/j.bmc.2010.05.015","volume":"18","author":"Sharma A.","year":"2010","unstructured":"Sharma A, Chakravarti B, Gupta MP, Siddiqui JA, Konwar R, Tripathi RP. Bioorg Med Chem, Synthesis and anti breast cancer activity of biphenyl based chalcones.,, 2010, 18,, 4711-4720,","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.canlet.2014.08.041","volume":"354","author":"Lee J.M.","year":"2014","unstructured":"Lee JM, Lee MS, Koh D, Lee YH, Lim Y, Shin SY. Cancer Lett, A new synthetic 2\u2032-hydroxy-2,4,6-trimethoxy-5\u2032,6\u2032-naphthochalcone induces G2\/M cell cycle arrest and apoptosis by disrupting the microtubular network of human colon cancer cells.,, 2014, 354,, 348-354,","journal-title":"Cancer Lett"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejmech.2014.03.002","volume":"77","author":"Mai C.W.","year":"2014","unstructured":"Mai CW, Yaeghoobi M, Abd-Rahman N, Kang YB, Pichika MR. Eur J Med Chem, Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.,, 2014, 77,, 378-387,","journal-title":"Eur J Med Chem"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/162409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T22:49:22Z","timestamp":1661294962000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/162409\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406414666180524074648","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}